The results of the various programs in international collaboration with Europe and the European Commission, in which the Fonds de recherche du Québec – Santé (FRQS) is a partner, are now revealed. Within the framework of the joint transnational calls launched in 2022, three (3) programs have seen results in the following areas: Neuroscience, Rare Diseases, and Personalized Medicine.
| Name of the candidate | Institution | Title of the project |
| ERA-NET NEURON (JTC 2022) – Neuroscience Network | ||
| Mindy Levin | McGill University | Comparative study of the mechanism of action of Dry Needling and Botulinum Toxin type A as a treatment for lower limb post-stroke spasticity: a proof of concept controlled trial (STROKE-POC) |
| Ravi Rungta | Université de Montréal | MICROglia as modulators of brain BLEEDs (MICROBLEEDs) |
| ERA-NET ERAPerMed (JTC2022) – Personalized Medicine.Network | ||
| François-Michel Boisvert | Université de Sherbrooke | Urine biomarkers for bladder cancer initial detection and surveillance: a multicentric study to assess the diagnostic accuracy of a comprehensive tool (UBIOBCA) |
| EJP RD (JTC 2022) – Rare Diseases Network | ||
| Arnaud Droit | Université Laval | Development of diagnostic solutions for neurodevelopmental disorders caused by ubiquitin-proteasome system dysfunction (UPS-NDDiag) |
| *EJP RD is a partnership program offered in co-funding with CIHR | ||
| Total contribution of the FRQS | 1.12 M$ | |
For any additional information, you can contact:
FRQS
Maxime Beaudoin
Programs Manager
514 873-2114 EXT 4369